IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

NCT06677710 · clinicaltrials.gov ↗

PHASE1

Phase

SUSPENDED

Status

34

Enrollment

INDUSTRY

Sponsor class

Stopped Business Reasons

Conditions

Multiple Sclerosis
Primary Progressive Multiple Sclerosis (PPMS)
Secondary Progressive Multiple Sclerosis (SPMS)
Non-Active Secondary Progressive Multiple Sclerosis
Non-Active SPMS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Autoimmune Diseases
Demyelinating Diseases
Immune System Diseases
Demyelinating Autoimmune Diseases, Central Nervous System (CNS)

Interventions

DRUG: IDP-023
DRUG: Ocrelizumab
DRUG: Interleukin-2
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Mesna

Sponsor

Indapta Therapeutics, INC.